ResMed (RMD) is a global leader in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD) and other chronic diseases. SDB includes obstructive sleep apnoea (OSA), and other respiratory disorders that occur during sleep. The company’s products and solutions are designed to improve patient quality of life, reduce the impact of chronic disease and lower healthcare costs as global healthcare systems continue to drive a shift in care from hospitals to the home and lower cost settings. ResMed’s cloud-based software digital health applications, along with its devices, are designed to provide connected care to improve patient outcomes and efficiencies for their customers. ResMed employs about 5,000 employees worldwide, operates in 100 countries and has manufacturing facilities in Australia, France, Singapore and the US. The ResMed share price is available at Capital.com.
最新股票文章

平頭哥分拆上市分析:阿里巴巴AI芯片業務的結構性風險與估值框架
阿里巴巴旗下平頭哥半導體擬分拆獨立上市,摩根大通估值介於250億至620億美元。本文從業務依賴度、估值方法論、地緣政策風險及港股科技板塊估值溢價等維度,解構該交易的結構性風險與分析框架。
14:16, 11 3月 2026


